Press Releases

Date Title and Summary View
Toggle Summary Zosano Pharma Granted Type C Meeting with FDA Regarding NDA Resubmission for M207 Following Preliminary Top-Line Pharmacokinetic Study Results
FREMONT, Calif. , Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the company has been granted a Type C written response only meeting with the U.S. Food and Drug Administration (“FDA”) regarding the resubmission
View HTML
Toggle Summary Zosano Pharma to Present at the H.C. Wainwright Virtual Global Investment Conference
FREMONT, Calif. , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo , will present a company overview at the H.C.
View HTML
Toggle Summary Zosano Pharma Reports Second Quarter 2021 Financial Results
FREMONT, Calif. , Aug. 10, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2021 , as well as business highlights. “We are pleased to have initiated the healthy
View HTML
Toggle Summary Zosano Pharma Announces Issuance of U.S. Patent for Method of Rapidly Achieving Therapeutic Levels with M207 for the Acute Treatment of Migraine
FREMONT, Calif. , July 20, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has been granted an additional patent covering method of use of M207 with the issuance of U.S. Patent No.
View HTML
Toggle Summary Zosano Pharma Announces Publication of Clinical Data Regarding the Long-term use of Qtrypta™ for the Treatment of Acute Migraine in The Journal of Headache and Pain
FREMONT, Calif. , May 26, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that an article titled, “Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatment of Migraine”
View HTML
Toggle Summary Zosano Appoints Industry Veteran, Kathy McGee, to its Board of Directors
FREMONT, Calif. , May 25, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Kathy McGee , an accomplished biopharmaceutical executive, to its board of directors. Ms.
View HTML
Toggle Summary Zosano Pharma Reports First Quarter 2021 Financial Results
FREMONT, Calif. , May 12, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2021 , as well as business highlights. “We have gained clarity from the FDA on the
View HTML
Toggle Summary Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA
– Company Establishes Agreement with Worldwide Clinical Trials to Conduct PK Study – – Anticipates initiating PK Study in June and Completion in Q3 2021 – FREMONT, Calif. , April 26, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today
View HTML
Toggle Summary Zosano Pharma Reports Fourth Quarter and Fiscal Year 2020 Financial Results
FREMONT, Calif. , March 11, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2020 , as well as business highlights.
View HTML
Toggle Summary Zosano Pharma to Present at the H.C. Wainwright Global Life Sciences Conference
FREMONT, Calif. , March 02, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo , will present a company overview at the H.C.
View HTML